$0.4593
0.02295.25%
Last update: Nov 9, 7:30 PM
Outlook Therapeutics Inc
OTLKNASDAQ
Outlook Therapeutics fell 63.5% from $1.26 to $0.46, behind the S&P 500's +10.5%. Its worst day was Jan 2 (−58.2%), and its low came Mar 24 at $0.20.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.19 beat the $-0.24 estimate on $-91,787.00 revenue (est. $6.0M).
−2.9% · S&P 500 +0.9%
Outlook Therapeutics shares fell 58.2%, while the S&P 500 rose 0.2%.
Story events cover the past 12 months · Times ET
−58.2%, the year's worst day · S&P 500 +0.2%
EPS of $-0.22 missed the $-0.17 estimate on $-1.2M revenue (est. $3.4M).
−13.8% · S&P 500 +0.2%
Outlook Therapeutics closed at its lowest level of the year, 84.3% below where the year started.
−38.1% · S&P 500 −0.3%
EPS of $-0.16 missed the $-0.12 estimate on $128,000.00 revenue (est. $4.4M).
+0.5% · S&P 500 −0.1%
Outlook Therapeutics shares rose 46.3%, while the S&P 500 fell 0.0%.
+46.3%, the year's best day · S&P 500 0.0%
Outlook Therapeutics shares rose 35.3%, while the S&P 500 fell 0.6%.
+35.3% · S&P 500 −0.6%
The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
−24.2% · S&P 500 0.0%
EPS of $-0.09 missed the $-0.08 estimate on $9,000.00 revenue (est. $1.0M).
−14.9% · S&P 500 −0.2%
Where it ended: a close of $0.46 on Nov 9, 2026. Up next: Q4 2026 earnings on Dec 18, 2026 (EPS est. $-0.08, revenue est. $2.2M).
Nothing in the past 12 months.
All OTLK dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OTLK and SPY from Benzinga historical bars. Not investment advice.
